ECPAS and cancer: In prostate cancer, Seki et al. [44, 45] revealed that miR-222 was able to directly target Ecm29 so as to significantly suppress cancer cell migration and invasion, but many other researchers have reported opposing results where miR-222 promoted prostate cancer cell proliferation or migration [14, 46].